Nansi S Boghossian1, Scott A McDonald2, Edward F Bell3, Waldemar A Carlo4, Jane E Brumbaugh3, Barbara J Stoll5, Abbot R Laptook6, Seetha Shankaran7, Michele C Walsh8, Abhik Das9, Rosemary D Higgins10. 1. Department of Epidemiology and Biostatistics, Arnold School of Public Health, University of South Carolina, Columbia. 2. RTI International, Research Triangle Park, North Carolina. 3. Department of Pediatrics, University of Iowa, Iowa City. 4. Department of Pediatrics, University of Alabama at Birmingham. 5. Department of Pediatrics, University of Texas Health Science Center at Houston. 6. Department of Pediatrics, Warren Alpert Medical School of Brown University and Women & Infants Hospital of Rhode Island, Providence. 7. Department of Pediatrics, Wayne State University, Detroit, Michigan. 8. Department of Pediatrics, Case Western Reserve University, University Hospitals Case Medical Center, Cleveland, Ohio. 9. RTI International, Rockville, Maryland. 10. Eunice Kennedy Shriver National Institute of Child Health and Human Development, Bethesda, Maryland.
Abstract
IMPORTANCE: Little is known about the effects of antenatal corticosteroids (ANS) on extremely preterm multiples. OBJECTIVE: To examine if use of ANS is associated with improvement in major outcomes in extremely preterm multiples. DESIGN, SETTING, AND PARTICIPANTS: Infants with a gestational age between 22 and 28 weeks born at a National Institute of Child Health and Human Development Neonatal Research Network center were studied between January 1998 and December 2013. Generalized estimating equation models were used to generate adjusted relative risks (aRR) controlling for important maternal and neonatal variables. EXPOSURE: Antenatal corticosteroids. MAIN OUTCOMES AND MEASURES: In-hospital mortality and the composite outcome of neurodevelopmental impairment at 18 to 22 months' corrected age or death before assessment. RESULTS: A total of 6925 multiple-birth infants were studied; 5775 of 6925 (83.4%) were twins, and 4276 (61.7%) were white. Of the total study population, 6094 (88%) were born to women who received ANS. In-hospital mortality was lower among infants with exposure to ANS vs no exposure (aRR = 0.87; 95% CI, 0.78-0.96). Neurodevelopmental impairment or death was not significantly lower among those exposed to ANS vs no exposure (aRR = 0.93; 95% CI, 0.84-1.03). Other adverse outcomes that occurred less frequently among infants of women receiving ANS included severe intraventricular hemorrhage (aRR = 0.68; 95% CI, 0.58-0.78) and the combined outcomes of necrotizing enterocolitis or death and severe intraventricular hemorrhage or death. Subgroup analyses indicated that exposure to ANS was associated with a lower risk of mortality and a lower composite of neurodevelopmental impairment or mortality among nonsmall for gestational age multiples (aRR = 0.82; 95% CI, 0.74-0.92; and aRR = 0.89; 95% CI, 0.80-0.98, respectively) and a higher risk among small for gestational age multiples (aRR = 1.40; 95% CI, 1.02-1.93; and aRR = 1.62; 95% CI, 1.22-2.16, respectively). Antenatal corticosteroids were associated with higher neurodevelopmental impairment or mortality among multiple-birth infants of mothers with diabetes (aRR = 1.55; 95% CI, 1.00-2.38) but not among infants of mothers without diabetes (aRR = 0.91; 95% CI, 0.83-1.01). CONCLUSIONS AND RELEVANCE: Compared with no exposure, exposure to ANS was associated with a lower risk of mortality in extremely preterm multiples, with no significant differences in the composite of neurodevelopmental impairment or death. Future research should investigate the increased risks of mortality and the composite of neurodevelopmental impairment or death associated with exposure to corticosteroids among small for gestational age multiples.
IMPORTANCE: Little is known about the effects of antenatal corticosteroids (ANS) on extremely preterm multiples. OBJECTIVE: To examine if use of ANS is associated with improvement in major outcomes in extremely preterm multiples. DESIGN, SETTING, AND PARTICIPANTS: Infants with a gestational age between 22 and 28 weeks born at a National Institute of Child Health and Human Development Neonatal Research Network center were studied between January 1998 and December 2013. Generalized estimating equation models were used to generate adjusted relative risks (aRR) controlling for important maternal and neonatal variables. EXPOSURE: Antenatal corticosteroids. MAIN OUTCOMES AND MEASURES: In-hospital mortality and the composite outcome of neurodevelopmental impairment at 18 to 22 months' corrected age or death before assessment. RESULTS: A total of 6925 multiple-birth infants were studied; 5775 of 6925 (83.4%) were twins, and 4276 (61.7%) were white. Of the total study population, 6094 (88%) were born to women who received ANS. In-hospital mortality was lower among infants with exposure to ANS vs no exposure (aRR = 0.87; 95% CI, 0.78-0.96). Neurodevelopmental impairment or death was not significantly lower among those exposed to ANS vs no exposure (aRR = 0.93; 95% CI, 0.84-1.03). Other adverse outcomes that occurred less frequently among infants of women receiving ANS included severe intraventricular hemorrhage (aRR = 0.68; 95% CI, 0.58-0.78) and the combined outcomes of necrotizing enterocolitis or death and severe intraventricular hemorrhage or death. Subgroup analyses indicated that exposure to ANS was associated with a lower risk of mortality and a lower composite of neurodevelopmental impairment or mortality among nonsmall for gestational age multiples (aRR = 0.82; 95% CI, 0.74-0.92; and aRR = 0.89; 95% CI, 0.80-0.98, respectively) and a higher risk among small for gestational age multiples (aRR = 1.40; 95% CI, 1.02-1.93; and aRR = 1.62; 95% CI, 1.22-2.16, respectively). Antenatal corticosteroids were associated with higher neurodevelopmental impairment or mortality among multiple-birth infants of mothers with diabetes (aRR = 1.55; 95% CI, 1.00-2.38) but not among infants of mothers without diabetes (aRR = 0.91; 95% CI, 0.83-1.01). CONCLUSIONS AND RELEVANCE: Compared with no exposure, exposure to ANS was associated with a lower risk of mortality in extremely preterm multiples, with no significant differences in the composite of neurodevelopmental impairment or death. Future research should investigate the increased risks of mortality and the composite of neurodevelopmental impairment or death associated with exposure to corticosteroids among small for gestational age multiples.
Authors: Praveen Ballabh; E S Lo; J Kumari; T B Cooper; I Zervoudakis; P A M Auld; A N Krauss Journal: Clin Pharmacol Ther Date: 2002-01 Impact factor: 6.875
Authors: Waldemar A Carlo; Scott A McDonald; Avroy A Fanaroff; Betty R Vohr; Barbara J Stoll; Richard A Ehrenkranz; William W Andrews; Dennis Wallace; Abhik Das; Edward F Bell; Michele C Walsh; Abbot R Laptook; Seetha Shankaran; Brenda B Poindexter; Ellen C Hale; Nancy S Newman; Alexis S Davis; Kurt Schibler; Kathleen A Kennedy; Pablo J Sánchez; Krisa P Van Meurs; Ronald N Goldberg; Kristi L Watterberg; Roger G Faix; Ivan D Frantz; Rosemary D Higgins Journal: JAMA Date: 2011-12-07 Impact factor: 56.272
Authors: Helen L Torrance; Jan B Derks; Sicco A Scherjon; Lia D Wijnberger; Gerard H A Visser Journal: Acta Obstet Gynecol Scand Date: 2009 Impact factor: 3.636
Authors: Robert L Schelonka; Waldemar A Carlo; Charles R Bauer; Myriam Peralta-Carcelen; Vivien Phillips; Jennifer Helderman; Christina T Navarrete; J Randall Moorman; Douglas E Lake; John Kattwinkel; Karen D Fairchild; T Michael O'Shea Journal: J Pediatr Date: 2020-02-04 Impact factor: 4.406
Authors: Jonathan L Slaughter; Clifford L Cua; Jennifer L Notestine; Brian K Rivera; Laura Marzec; Erinn M Hade; Nathalie L Maitre; Mark A Klebanoff; Megan Ilgenfritz; Vi T Le; Dennis J Lewandowski; Carl H Backes Journal: BMC Pediatr Date: 2019-09-13 Impact factor: 2.125
Authors: Nir Melamed; Elizabeth Asztalos; Kellie Murphy; Arthur Zaltz; Donald Redelmeier; Baiju R Shah; Jon Barrett Journal: BMJ Open Date: 2019-09-30 Impact factor: 2.692